The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
|Videos|August 1, 2017
Dr. du Bois on Study of Secondary Cytoreductive Surgery in Ovarian Cancer
Author(s)Andreas du Bois, MD, PhD
Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses his study of secondary cytoreductive surgery in ovarian cancer.
Advertisement
Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses his study of secondary cytoreductive surgery in ovarian cancer.
In a randomized controlled phase III study, investigators evaluated the impact of secondary cytoreductive surgery in patients with recurrent ovarian cancer.
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5